📜 What This Document Is 📰

This document is a highly technical piece of legal paperwork, specifically an exhibit to an 8-K (Current Report) filing. Essentially, it is a Securities Purchase Agreement. This agreement governs a large "private placement," which means the company (Enveric Biosciences) is raising money by selling its securities directly to a select group of investors, rather than selling them to the general public.

You should expect to learn the specific rules and terms that define how the money exchange will happen, what types of shares are being sold, and the legal assurances that the company is making to the investors. 👉 Why this matters: This document is the blueprint for the capital raise, telling the market exactly what Enveric is giving up and what the investors are paying.

🏢 Enveric Biosciences: Company Overview 🔬

While the filing is primarily legal, it establishes that Enveric Biosciences, Inc. is a company engaged in the pharmaceutical and biotech sector, indicated by the mentions of "Pharmaceutical Product" and compliance with the FDA. The company's operations are complex, involving multiple subsidiaries and highly regulated industries.

The core business involves advanced scientific and pharmaceutical development, which is suggested by the comprehensive need to comply with rules governing clinical trials, manufacturing, and drug safety. 👉 In simple terms: Enveric is a pharmaceutical developer that needs large amounts of capital to fund its drug research and operations.

💰 📈 The Core Transaction Details 💸

The central purpose of this agreement is the sale of securities from Enveric to specific "Purchasers." This is a private funding round designed to bring in capital needed for the company’s continued operations and growth. The total funding targeted is significant, with the agreement setting an aggregate purchase amount of up to $5,000,002.

The exchange is highly structured: the Purchasers deliver funds (the Subscription Amount), and the Company delivers the securities (Shares and Warrants). 👉 What this signals: By locking in up to $5 million, the company is securing substantial, non-diluted capital from sophisticated investors at a defined price.

🧬 Securities Being Sold 🗃️

Enveric is not just selling standard shares of stock; the deal involves several complex types of securities, which essentially give the investors multiple ways to benefit from the company's success.

• Common Stock (Shares): This is the foundational equity in the company. The agreed-upon initial purchase price for the common stock is $2.25 per share, though this price is subject to future adjustments from corporate actions like stock splits.
• Warrants (Series I & Series J): These are the rights to purchase more stock at a specified price in the future.
  • Series I Warrants: These have a long term of exercise, equal to five (5) years after the Resale Registration Statement is effective.
  • Series J Warrants: These have a shorter term of exercise, equal to eighteen (18) months after the Resale Registration Statement is effective.
• Pre-Funded Warrants: These are a specialized type of warrant that allows the investor to immediately treat the purchase as if they bought the underlying shares, often used to help structure the deal for large investors.

👉 Why the distinction matters: The fact that the deal involves warrants with different expiry dates (5 years vs. 18 months) shows a sophisticated structure, allowing the investors to defer their investment risks while providing immediate capital to the company.

🔑 The Mechanics and Closing Process ⚙️

The agreement outlines specific conditions that must be met for the transaction to legally complete (the "Closing Date"). These mechanisms are designed to protect both the company and the investors.

• Role of Agents: The deal is facilitated by a Placement Agent, H.C. Wainwright & Co., LLC, who helps structure and sell the securities. The money and documentation are managed by the Escrow Agent, Continental Stock Transfer & Trust Company.
• Closing Conditions: The Company's obligations (like having proper legal standing and having no "Material Adverse Effect") must be met, and the Purchasers' obligations (like providing the funds and executing the agreements) must also be satisfied.
• Delivery: The closing involves the Company delivering the Shares, Warrants, and other key documents, while the Purchasers deliver the required Subscription Amount via wire transfer.

🛡️ Corporate Legal Guarantees and Compliance 🙏

The bulk of the filing consists of detailed legal representations and warranties. These are essentially legal promises—guarantees that the company is legally sound, honest, and compliant. If the company were found to be lying about these points later, the investors would have legal recourse.

The company makes extremely broad guarantees regarding its status, including:

• Good Standing: The Company guarantees it is legally incorporated and operates properly in all required jurisdictions.
• No Conflicts: It confirms that the sale of these securities does not violate any of its existing organizational documents or agreements.
• Financial Health: The company guarantees that its assets, cash flow, and legal structures are strong enough to cover its debt and continue operating after the funds are received.
• Regulatory Compliance: The Company guarantees compliance with major federal laws, such as:
  • FDA: Compliance with the Federal Food, Drug and Cosmetic Act for all pharmaceutical products.
  • FCPA: Compliance with the Foreign Corrupt Practices Act (rules against bribery).
  • SOX: Maintaining strong internal accounting controls (Sarbanes-Oxley Act).
  • Data Privacy: Compliance with global data privacy laws, including the European Union General Data Protection Regulation (GDPR).

👉 Why this matters: These warranties reduce risk for the investors. They are ensuring that the company isn't facing hidden lawsuits, environmental liabilities, or regulatory shutdowns that would undermine the investment.

📝 Other Key Legal Points 🔍

The agreement also contains several highly detailed legal points meant to protect the transaction and the parties involved:

• Anti-Takeover Protection: The Company states that it has taken steps to ensure that the private funding round will not trigger any restrictive anti-takeover provisions (like "poison pills").
• No Material Non-Public Information: The Company guarantees that all information provided to the investors is accurate and that no material, non-public information was exchanged.
• Market Integrity: The document explicitly notes that past or future open market activities by the Purchasers, such as short selling, may negatively impact the company's stock price.

📞 Key Contacts and Advisors 🧑‍💼

The deal relies on a highly specialized team of professional advisors.

• Placement Agent: H.C. Wainwright & Co., LLC
• Company Counsel: Greenberg Traurig, LLP
• Escrow Agent: Continental Stock Transfer & Trust Company

🧠 The Analogy 🏞️

Think of this private placement like selling a share of a professional kitchen to a group of venture capitalists (the Purchasers). Instead of just handing over a key (the shares), you are giving them three things: the kitchen itself (the common stock), the right to buy more kitchen equipment later (warrants), and a deposit that counts toward future equipment purchases (pre-funded warrants). The legal agreement is the binding contract that guarantees that the kitchen is structurally sound, all the plumbing and electrical codes (FDA/SOX/GDPR) are up to date, and that the transaction is above board.

🧩 Final Takeaway ✨

Enveric Biosciences completed a significant private placement, raising capital up to $5,000,002 by selling multiple classes of securities (Shares, Series I, Series J, and Pre-Funded Warrants) at a $2.25 per-share price. The filing's purpose was not to report performance, but to establish the iron-clad legal framework that guarantees the company’s financial stability, regulatory compliance, and the terms for the capital infusion.